Contact dermatitis

disease

On this page

Also known as contact eczema

Summary

Contact dermatitis (MONDO:0005480) is a disease with 2 GWAS associations across 13 studies and 25 clinical trials. Top therapeutic interventions include aluminum chloride, petrolatum, and vehicle. A subtype of dermatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

GWAS associations: 2
Clinical trials: 25

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	contact dermatitis
Mondo ID	MONDO:0005480
EFO	EFO:0005319
MeSH	D003877
DOID	DOID:2773
NCIT	C26743
SNOMED CT	40275004
UMLS	C0011616
MedGen	8329
Is cancer (heuristic)	no

Also known as: contact dermatitis · contact eczema

Data availability: 2 GWAS associations (13 studies).

Disease family

This is a subtype of dermatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › contact dermatitis

Subtypes (4): contact dermatitis due to nickel, allergic contact dermatitis, irritant dermatitis, occupational dermatitis

Genetics & variants

GWAS landscape

2 GWAS associations across 13 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs61816761	3e-12	FLG, CCDST	A	0.74
rs186412581	5e-09	AHR	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90018830	Sakaue S	2021	3,691	475,075	A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90473924	UK Biobank Whole-Genome Sequencing Consortium	2025	3,090	455,350	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90479302	Verma A	2024	1,958	442,825	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473923	UK Biobank Whole-Genome Sequencing Consortium	2025	1,429	457,011	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90080339	Backman JD	2021	799	382,796	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084325	Backman JD	2021	799	382,796	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90651391	Liu TY	2025	383	199,253	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90480824	Verma A	2024	283	120,595	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90482550	Verma A	2024	283	120,595	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90018610	Sakaue S	2021	247	161,777	A cross-population atlas of genetic associations for 220 human phenotypes.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
stop_gained	1
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs61816761	1	152313385	G>A,C,T	0.05	stop_gained	FLG, CCDST	3e-12	Tier 1: coding
rs186412581	7	17087016	A>G,T		intron_variant	AHR	5e-09	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

4 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cortisone Acetate	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 25.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	16
PHASE1	4
PHASE2	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00640614	PHASE3	COMPLETED	Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy
NCT01518348	PHASE3	WITHDRAWN	Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents
NCT00640250	PHASE2	COMPLETED	Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
NCT02028182	PHASE2	COMPLETED	Clinical Evaluation of Lyral® Dose Response Study
NCT02028208	PHASE2	COMPLETED	Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
NCT00614289	PHASE1	COMPLETED	Novel Topical Treatment of Hand Dermatitis (Eczema)
NCT02700373	PHASE1	COMPLETED	A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers
NCT03089775	PHASE1	COMPLETED	Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis
NCT04853823	PHASE1	UNKNOWN	A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB
NCT07183423	Not specified	RECRUITING	Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
NCT07338305	Not specified	ACTIVE_NOT_RECRUITING	Methotrexat to Hand Eczema in the BIOSKIN Cohort
NCT00371163	Not specified	COMPLETED	Molecular and Cellular Characterization of Spongiotic Dermatitis
NCT00646867	Not specified	COMPLETED	Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis
NCT00824889	Not specified	COMPLETED	Exploratory Study of Natural Killer Cells in Human Skin
NCT02026700	Not specified	UNKNOWN	Bariederm Cream in Chronic Contact Dermatitis
NCT03198390	Not specified	TERMINATED	Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions
NCT03705182	Not specified	UNKNOWN	Prevention of Dermatitis in Epoxy Exposed Workers
NCT04438135	Not specified	COMPLETED	Children With Aluminium Contact Allergy: Cutaneous Exposure Study
NCT04772482	Not specified	COMPLETED	Study on Hypoallergenic Hair Dye
NCT04921163	Not specified	COMPLETED	Children With Aluminium Contact Allergy: Oral Exposure Study
NCT06177314	Not specified	UNKNOWN	Molecular Diagnosis of Allergic Contact Dermatitis
NCT06189144	Not specified	UNKNOWN	Testing an Intervention in Irritative Contact Dermatitis
NCT06331390	Not specified	UNKNOWN	Assessment of Niacinamide Cosmetic Product Efficacy in Model of Irritant Contact Dermatitis
NCT06387472	Not specified	COMPLETED	DermAI to Evaluate Human Factor of Testing
NCT07066150	Not specified	COMPLETED	A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALUMINUM CHLORIDE	4	1
PETROLATUM	3	1
VEHICLE	0	1
MERCURY, AMMONIATED	-1	1

Drugs: Aluminum Chloride, Petrolatum